Skip to main content

Table 2 SHFS and SHS participant sphingolipid concentrations (µM)

From: Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study

 

SHFS (n = 597)

SHS controls (n = 189)

SHS cases (n = 78)

Mean

SD

Range

90th/10th pct

Mean

SD

Range

90th/10th pct

Mean

SD

Range

90th/10th pct

Cer-16

0.20

0.07

0.06–0.58

2.2

0.32

0.08

0.13–0.64

1.9

0.33

0.09

0.16–0.6

2.2

Cer-20

0.07

0.03

0.01–0.29

2.8

0.11

0.04

0.04–0.38

2.5

0.11

0.04

0.06–0.27

2.2

Cer-22

0.81

0.33

0.23–3.16

2.5

0.76

0.22

0.34–1.84

1.9

0.74

0.22

0.29–1.43

2.1

Cer-24

5.62

2.06

1.75–18.96

2.4

5.15

1.36

2.33–9.94

1.9

5.06

1.41

2.23–9.93

1.9

SM-16

135.21

28.73

59.79–275.51

1.6

131.37

18.38

84.36–186.86

1.4

134.74

25.97

76.13–226.01

1.6

SM-20

20.33

5.00

8.76–44.53

1.9

15.70

3.17

9.17–23.97

1.8

15.15

3.49

6.65–28.98

1.7

SM-22

35.82

9.40

13.09–76.09

1.9

26.21

5.52

14.03–39.15

1.8

25.23

6.06

12.41–48.77

1.8

SM-24

19.36

5.45

7.35–44.67

2.0

14.06

3.36

7.3–23.76

1.8

13.42

3.42

6.46–24.12

1.9

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840